Cost of rimegepant and lasmiditan associated adverse events, for acute treatment in migraine in Spain
In accordance with this model, the favorable safety profile of RIM compared to LAS would generate savings for the SNHS in health-care resources in all the scenarios considered.
Authors
- Carlota Moya-Alarcón (ORCID: https://orcid.org/0000-0003-4873-7362)
- Darío Rubio-Rodríguez
- Beatriz Armada (ORCID: https://orcid.org/0000-0002-2730-3090)
- Pablo Irimia
- Carlos Rubio-Terres
- Sonia Santos Lasaosa
Institutions
- Pfizer (United States) (US)
- Universidad de Zaragoza (ES)
- Clinica Universidad de Navarra (ES)
- Instituto de Investigación Sanitaria Aragón (ES)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2026-01-09
- DOI
- https://doi.org/10.1080/14737167.2026.2615680
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00